N/A

What if researchers could take the antibody-drug conjugate model and apply it to off-the-shelf NK cell therapy? For the Taiwan-based biotech Acepodia, that’s the …

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine,

On March 8^th, 2021, SyneuRx announced that the Taiwan FDA has granted its IND applications of two phase IIb/III clinical trials: ClozaBen^® (SND12) for the treatment of refractory schizophrenia in adults, and NaBen^® (SND13) as an add-on therapy for adult schizophrenia.

N/A

Taipei, Taiwan and Ahmedabad, March 4^th, 2021 – Foresee Pharmaceuticals (6576.TWO) (“Foresee”) announced today that it has entered into an exclusive license agreement with Intas Pharmaceuticals (“Intas”) for the US commercialization of Foresee’s novel FP-001 program, Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous 6-month and 3-month depot formulations (“Camcevi^®”).

SyneuRx (TT6575) presents an important progress report in the “2021 Joint Spring Congress & Non-invasive Brain Stimulation Workshop” (2021.02.27.), held by Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN), with the title of “The Omega Form of Sodium Benzoate (Ω-NaBen), a Novel Polymorphic Form, Shows Improved Solubility, Bioavailability and Antipsychotic Effects.”

With its ongoing Phase 1 clinical trial of ACE1702 for the treatment of HER2-expressing solid tumors, Acepodia hopes to make a case for fast, affordable, and effective off-the-shelf cell therapies.

Natural killer (NK) cells, as a potential source for off-the-shelf cell therapy, attack tumor cells with low risk of severe cytokine release syndrome (CRS) or graft-versus-host disease (GvHD).

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announces its financial results for the fiscal year ended October 31, 2020 and provides a business update.